Introduction
Up to 36% of patients diagnosed with pheochromocytoma or paraganglioma will develop metastatic disease and have a 5-year survival of w50% (O'Riordain et al. 1996 , Mundschenk & Lehnert 1998 , John et al. 1999 , Plouin et al. 2000 , Lenders et al. 2005 , Adjalle et al. 2009 , Gaal et al. 2010 . Moreover, patients with metastatic pheochromocytoma and paraganglioma often exhibit excessive levels of circulating catecholamines. This results in an increased risk of hypertensive complications, including stroke, myocardial infarction, and tachyarrhythmia. Current treatments for malignant pheochromocytoma or paraganglioma include targeted radiation using [
131 I]meta-iodobenzylguanidine ([ 131 I]MIBG), cytotoxic chemotherapy, the somatostatin analog octreotide, chemoembolization, and less commonly, radiofrequency or cryoablation (Averbuch et al. 1988 , Kopf et al. 1997 , Loh et al. 1997 , Sisson et al. 1999 , Takahashi et al. 1999 , Pacak et al. 2001a , Munver et al. 2003 . The most common chemotherapeutic regimen used for metastatic pheochromocytoma and paraganglioma is a combination of cyclophosphamide, vincristine, and dacarbazine (CVD). A long-term follow-up study conducted on 18 patients reported a complete response rate of 11% and a partial response rate of 44% of metastatic pheochromocytoma and paraganglioma patients after CVD treatment (Huang et al. 2008) . However, the survival rate did not differentiate between those patients treated with or without CVD chemotherapy, also described by a recent study (Huang et al. 2008 , Nomura et al. 2009 ).
Among current therapeutic options for metastatic pheochromocytoma and paraganglioma, [
131 I]MIBG is still the most effective therapy because it specifically targets tumor cells via the membrane norepinephrine transporter system (Sisson & Wieland 1986 , Sisson et al. 1987 , Glowniak et al. 1993 , Rose et al. 2003 , Gonias et al. 2009 , Shilkrut et al. 2010 131 I]MIBG, and cure is extremely rare (Loh et al. 1997) . This disappointing response rate is likely related to reduced expression of the norepinephrine transporter and the number of catecholamine storage granules in metastatic tumor that results in suboptimal [
131 I]MIBG concentrations within the tumor cells. Furthermore, the low-specific activity of most preparations of [ 131 I]MIBG causes a low accumulation of radioactivity in pheochromocytoma due to significant competitive uptake with unlabeled MIBG. In addition, elevated circulating catecholamines in these patients compete with [
131 I]MIBG for transporter-mediated uptake by the tumor cells, further reducing uptake of the therapeutic agent (Eldadah et al. 2004) . Finally, proper function of vesicular uptake is also important, which is well supported by the work of Kolby et al. (2003) , indicating the importance of secretory granules containing vesicular monoamine transporters for the uptake and retention of [ 123/131 I]MIBG. A number of histone deacetylase (HDAC) inhibitors have demonstrated activity as anticancer agents. Romidepsin (depsipeptide, FR901228), a complex cyclic peptide isolated from Chromobacterium violaceum, has demonstrated potent antitumor activity in vitro and against human tumor xenografts (Marks et al. 2000) and in murine tumors in vivo (Ueda et al. 1994a,b) . Laboratory studies have demonstrated that romidepsin, similar to other HDAC inhibitors, induces expression of a specific subset of genes involved in cell growth inhibition and induction of differentiation (Van Lint et al. 1996) . Romidepsin is able to cause both a p21-dependent G1 and p21-independent G2 arrest, with the G2 arrest appearing more cytotoxic than the G1 arrest (Sandor et al. 2000a,b) .
By extension, HDAC inhibitors might also benefit the treatment of metastatic pheochromocytoma and paraganglioma by virtue of their ability to induce growth inhibition and/or apoptosis in pheochromocytoma cells, increase the entry and retention of radioisotopes (e.g. [
131 I]MIBG), and stimulate the differentiation of malignant pheochromocytoma and paraganglioma cells with partial or total restoration of the phenotypic traits of the normal chromaffin cell (Li et al. 2002) . From previous work we learned that romidepsin was able to differentiate thyroid cancer cells and to increase the entry of 131 I into these cells in patients with negative 131 I scan (Kitazono et al. 2001 , Furuya et al. 2004 ). We also learned that HDAC L Martiniova, S M Perera et al.: Histone deacetylase inhibitors and PHEO www.endocrinology-journals.org inhibitors were able to increase the efficacy of cisplatin, a compound that is known to increase the expression of norepinephrine transporters (Kim et al. 2003 , Cleary & Phillips 2006 . HDAC inhibitors are also known to enhance a cocaine-induced antidepressant effect of stress (Kumar et al. 2005) . All these effects and unpublished preliminary findings of the NIH investigators suggested that HDAC inhibitors could potentially affect norepinephrine transporters in chromaffin or neuronal cells, which led us to hypothesize that HDAC inhibitors might increase the expression of norepinephrine transporters and thus increase the entry of [
131 I]MIBG into pheochromocytoma cells. In this study, we examined the effects of two unrelated HDAC inhibitors, romidepsin and trichostatin A, in mouse pheochromocytoma (MPC) cells in vitro and a MPC mouse model of metastatic pheochromocytoma (Ohta et al. 2008 , Martiniova et al. 2009b 
Materials and methods

Reagents
RPMI 1640, DMEM, trypsin-EDTA, penicillin/streptomycin 100!, and 1 M HEPES buffer were purchased from Invitrogen-Life Technologies. Fetal bovine serum (FBS) and donor horse serum (DHS) were obtained from Gemini Bio-Products (Woodland, CA, USA). L-2, 5, 6-3 H-norepinephrine was purchased from NEN Life Science Products (Boston, MA, USA). BSA, dimethyl sulfoxide, and all the components of the Krebs Ringer Glucose (H-KRG) buffer were purchased from Sigma Chemical Co. PBS was obtained from Biosource International (Camarillo, CA, USA), and Triton X-100 was obtained from Fisher Scientific (Suwanee, GA, USA). Romidepsin was kindly provided by the Developmental Therapeutics Program, National Cancer Institute (Bethesda, MD, USA). Trichostatin A was purchased from Sigma Chemical Co.
Cell culture
MPC cells (cell line 4/30/PRR) were established from heterozygous neurofibromatosis knockout mice (Powers et al. 2000) . Cells were cultured in RPMI 1640 supplemented with 10% DHS, 5% FBS with penicillin/streptomycin, and maintained at 37 8C in 5% CO 2 . Cells from passages 26-38 were used in the experiments.
Cell proliferation assay
The cytotoxic effects of romidepsin and trichostatin A were examined using the XTT-assay (Cell Proliferation kit II, Roche Applied Science). MPC cells were seeded into 96-well flat-bottomed plates at 50 000 cells/well and incubated with increasing concentrations of romidepsin or trichostatin A diluted in medium at 37 8C for 48 or 72 h. The XTT mixture was then added, and the cells were incubated for 18 h. After incubation, the absorbance at 690 nm was measured using a microplate reader (Bio-Rad Laboratories). All experiments were performed in octuplicate.
Uptake of [ 3 H]norepinephrine
The uptake of norepinephrine by MPC cells was determined using [ 3 H]norepinephrine and following a modification of the protocol described by Jaques et al. (1984) . MPC cells (100 000 cells/well) in 24-well plates were incubated with increasing concentrations of romidepsin from 0.001 to 10 ng/ml or trichostatin A at 6.25-100 ng/ml diluted in the medium for 48 or 72 h at 37 8C. After treatment, cells were washed three times with 0.5 ml H-KRG buffer (H-KRG: 125 mM NaCl, 4.8 mM KCl, 2.6 mM CaCl 2 , 1.2 mM MgSO 4 , 5.6 mM glucose, 25 mM HEPES, 1 mM ascorbic acid, pH 7.35), followed by a 10 min preincubation in H-KRG buffer (0.5 ml/well) at 37 8C.
Next, [
3 H]norepinephrine (25 nM/well) was added and the cells were incubated at 37 8C for 10 min. [ 3 H]norepinephrine uptake was stopped by rapidly chilling the plates on ice, and the cells were washed twice with 0.1% albumin in PBS at 4 8C. Cells were lysed with 0.5 ml Triton-X100 (0.1%) and aliquots of the cell lysates were transferred into scintillation vials. After addition of the Biosafe-II scintillation cocktail (Research Products International, Mount Prospect, IL, USA), cell-associated b radiation was counted in a b-counter (Beckman Coulter LS 60000 IC). ]MIBG uptake was stopped by rapidly chilling the plates on ice, and the cells were washed twice with 0.1% albumin in PBS at 4 8C. The incubation medium was collected, and the cells were washed with cold PBS, trypsinized, and the cell-associated radioactivity was measured using a g-counter (1480 Wizard 3, Automatic Gamma Counter, PerkinElmer, Waltham, MA, USA).
In a subset of experiments, uptake studies with romidepsin and trichostatin A treatment were carried out in the presence or absence of 1 mM desipramine to block catecholamine uptake (Lingen et al. 1994) , or 10 mM reserpine to block vesicular catecholamine translocation (Eisenhofer et al. 1989 , Cornelissen et al. 1997 . All experiments were performed in quadruplicate.
Protein collection and analysis
For these experiments, cells were incubated in 25 ml flasks with 0, 0.25, 0.5, or 0.75 ng/ml of romidepsin or 0, 6.25, 12.5, or 25 ng/ml of trichostatin A for 72 h. After two washes with PBS, cells were pelleted and lysed. Cell lysates were added to the loading buffer (1:1 GTC/PBS, Invitrogen/Cellgro). The samples were serially diluted 1:2 and loaded into a 96-well vacuum manifold (Bio-Rad) with two sheets Protran membrane (Schleicher & Schuell, Keene, NH, USA), and a vacuum was slowly applied. The membrane was removed and washed twice in TBS before being probed for GAPDH at 1:500 (American Research Products, Belmont, MA, USA). After antibody binding, the membrane was washed three times in TTBS. The blot was then incubated with HRP-linked anti-mouse Ig whole antibody at 1:1000 (Amersham) and imaged using ECL western blotting kit (Amersham). Next, the membrane was stripped using Re-Blot Plus Mild (Chemicon, Temecula, CA, USA) for 10 min. Subsequently, it was probed for anti-acetyl histone H3 1:2200 and again washed three times in TTBS, followed by HRP-linked anti-rabbit Ig whole antibody at 1:1000 (Amersham) and imaged as before. Densitometry was performed on films using the IPLab gel software.
Ultrastructural studies
The effect of treatment with either 0.5 ng/ml romidepsin or 12.5 ng/ml trichostatin A on MPC cell morphology and ultrastructure was examined by transmission electron microscopy. After three washes with PBS, cells were double-fixed in PBS-buffered glutaraldehyde (2.5%) and osmium tetroxide (0.5%), dehydrated, embedded into Spurr's epoxy resin, and coded to ensure unbiased assessment. Ultra thin sections (90 nm) were made and double-stained with uranyl acetate and lead citrate and viewed in a Philips CM10 transmission electron microscope.
Animal model
The metastatic MPC model used in this study was previously described (Martiniova et al. 2009a,b) . Briefly, female 6-8-week-old (20-22 g) athymic nude mice (NCr-nu; Taconic, Germantown, NY, USA) were injected through the tail vein with 1!10 6 MPC (MPC 4/30 PRR) cells. MPC cells were mixed with 100 ml PBS and held at room temperature prior to injection. Mice were anesthetized using isoflurane/O 2 (1.5-5% v/v) before all imaging and treatment procedures. All animal studies were conducted according to the National Institutes of Health Guide for the Care and Use of Animals under an approved protocol from the Institutional Animal Care and Use Committee.
In vivo magnetic resonance imaging
Magnetic resonance images were obtained with a 3T magnetic resonance imaging (MRI) scanner (Intera, Philips Medical System, Best, The Netherlands) using a dedicated 40 mm inner diameter solenoid coil (Philips). Localization and monitoring of liver lesions were carried out as previously described (Martiniova et al. 2009a) . Briefly, with anesthetized animals in the prone position, respiratory-triggered T 2 -weighted spectra were acquired with the following parameters: FOV 8.0!8.0!2.0 cm 3 , data matrix 512!512, 40 slices, TE/TR 65/4500 ms, flip angle 908, slice thickness 0.5 mm, 0.156!0.156 mm 2 in-plane resolution, scan time of 5-7 min for two signal averages depending on the respiratory rate. No contrast agent was used for MRI. Animals were scanned 4-5 weeks after the injection of MPC cells to determine the liver tumor size. romidepsin at a dose of 3.6 mg/kg; however, mice with extensive liver metastases did not tolerate this dose. Thus, a single lower dose of romidepsin, 2.5 mg/kg, was used to evaluate its effect on isotope accumulation in the tumors. The same concentration was used for trichostatin A. Both romidepsin and trichostatin A were diluted in saline and intravenously administered by injection of 150 ml at a rate of 10 ml/min. 18 F]fluorodopamine in the liver tumors and normal liver tissue were assayed using an automatic g-counter (Model 1480 Wallac Wizard, PerkinElmer, Shelton, CT, USA). Standards of 1:10 of the injected dose were prepared and counted along with all samples. Background counts were subtracted from the reported 123 I and 18 F counts per minute. The injected counts were determined from the standard counts and the quantitative data, expressed as percentage of injected dose per gram (%ID/g), were determined as previously described (Toyama et al. 2004) . Tumors were monitored using positron emission tomography (PET) imaging. The procedure for romidepsin pretreatment evaluation consisted of two PET scans, where mice were injected with 50-60 mCi (1850-2220 kBq) [
18 F]fluorodopamine, performed on the same mice. Mice were treated with a single dose of 2.5 mg/kg romidepsin (nZ4). The first scan was performed before the treatment as a baseline measurement. One week later, a second scan 24 h after treatment with romidepsin was performed on the same mice.
PET scans were performed using the Advanced Technology Laboratory Animal Scanner (ATLAS; Seidel 2003) , which has a transverse field-of-view (FOV) of 6.8 cm and an axial FOV of 2 cm. PET images were reconstructed by a 2D-ordered-subset expectation maximization (2D OSEM) algorithm (5 iterations and 16 subsets), achieving a 1.5 mm full width at half maximum (FWHM) resolution at the center (Toyama et al. 2004) . The reconstructed voxel size was 0.56!0.56!1.125 mm 3 . No correction was applied for attenuation or scatter. Dynamic data acquisition determining the pharmacokinetics of [ 18 F]fluorodopamine in liver tumors and liver parenchyma started about 1 min after injection. Scanning parameters were set for one frame/10 min, up to six frames. Whole body data acquisitions (two bed positions, each 10 min) started consecutively after the dynamic acquisition. Whole body acquisitions (achieving 2!2 cmZ4 cm of the field of view), including images of the lungs through the kidneys, were acquired after administration of 50-60 mCi (1850-2220 kBq) [
18 F]fluorodopamine. If liver tumors are smaller (in any dimension) than w2.5 times the FWHM of the spatial resolution of the PET scanner, a distortion called a partial volume effect occurs (Hutchins et al. 2008) . Therefore, liver lesions were analyzed only if they were larger than 4 mm in diameter as obtained by MRI. This is the minimum size required to exclude partial volume effects in small animal PET when monitoring lesions for potential physiological changes (Keyes 1995) . The [
18 F] activity concentration of the radionuclide was expressed as the tumor-to-liver ratio (TLR), which was obtained by comparing uptake in the liver lesions with that in the liver parenchyma. PET results are also expressed as standardized uptake value (SUV), which was determined as described previously (Green et al. 2001 ).
SYBR Green real-time PCR for quantification of norepinephrine transporter expression in liver tumors
Norepinephrine transporter expression was quantified by quantitative real-time PCR. Total RNA was extracted from isolated liver metastases of untreated control mice and from trichostatin A-treated mice using the RNeasy Midi kit (Qiagen) according to the manufacturer's instructions. After reverse transcribing mRNA, real-time PCR was performed in triplicate Endocrine-Related Cancer (2011) 18 143-157 www.endocrinology-journals.org using the SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, USA) in a 7500 Realtime PCR system (Applied Biosystems) as previously described (Ichijo et al. 2005) . Use of forward primer 5 0 -AGAGCAGTGGGATCCATGAC-3 0 and reverse primer 5 0 -CCAGGAGCACAAACAAGACA-3 0 yielded a 168 bp product. Obtained threshold cycle (C T ) values of the norepinephrine transporter gene in liver lesion samples after trichostatin A treatment (nZ7) were normalized to those of b-actin, and their relative mRNA expression was expressed as fold induction over the baseline of untreated controlliver lesions (nZ6). The dissociation curves of the primer pairs showed a single peak, and PCR produced a single expected DNA band in an agarose gel analysis. Statistical analyses were carried out by unpaired t-test with the two-tailed P value.
Data analyses
Results are presented as the meanGS.E.M. from a minimum of three experiments. Before performing any statistical test, all data were tested for normal distribution and equal variance. Statistical differences between groups of data were assessed by ANOVA, followed by the Student-Neuman-Keuls test for group comparison. The level of statistical significance was set at P!0.05.
Results
Romidepsin and trichostatin A demonstrated a dose-and time-dependent inhibition of MPC cell proliferation Treatment with romidepsin or trichostatin A both induced a dose-dependent decrease in MPC cell proliferation. Growth inhibition curves after 48 and 72 h of exposure to either drug are shown in Fig. 1A and B. After a 72 h exposure, the 50% inhibitory concentrations (IC 50 ) were determined to be 1.56 ng/ml for romidepsin and 50 ng/ml for trichostatin A.
Romidepsin and trichostatin A increased [ 3 H]norepinephrine-specific uptake in MPC cells A significant dose-and time-dependent increase in the [ 3 H]norepinephrine-specific uptake was observed in MPC cells treated with romidepsin at concentrations of 0.25-0.5 ng/ml, and trichostatin A concentrations of 6.25-12.5 ng/ml. This increase was followed by a decreased uptake at the highest concentrations of both tested drugs (Fig. 1C and D) . The maximal increase in 123 I]MIBG uptake in MPC cells occurred 72 h after treatment with 0.5 ng/ml romidepsin in both short-term ( Fig. 2A) and long-term (Fig. 2B) culture. Trichostatin A (12.5 ng/ml) resulted in approximately the same levels of [ 123 I]MIBG uptake after 48 h as after 72 h ( Fig. 2A and B) . The uptake of [ 123 I]MIBG in MPC cells was w3.6-fold higher than in the control group at 10 min, and 4.4-fold higher at 120 min after 72 h treatment with trichostatin A. Similarly, for romidepsin, the uptake of [ 123 I]MIBG was w1.5 times that in the control group at 10 min, and 2.2 times higher at 120 min.
In order to find out whether the increase in [ 123 I]MIBG uptake was due to inhibition of transport across the cell membrane or impaired granule storage, we examined the effect of desipramine on [
123 I]MIBG uptake and retention, and also the effect of reserpine on storage of [ 123 I]MIBG in vesicles. Desipramine inhibited the entry of [ 123 I]MIBG into both untreated and treated MPC cells; the inhibitory effect was more pronounced at 10 min than at 120 min ( Fig. 2A and B) . A similar, though less pronounced, inhibitory effect was observed with reserpine at 120 min in untreated cells, and at 10 and 120 min in cells treated with trichostatin A ( Fig. 2A and B) . Similarly, increased accumulation of [ 18 F]fluorodopamine was observed in MPC cells after treatment with romidepsin for 48 and 72 h (Fig. 2C) . Desipramine significantly inhibited the entry of [ 18 F]fluorodopamine into MPC cells (Fig. 2C) .
Romidepsin or trichostatin A treatment increased acetylation of histone H3
Blot analysis showed increased acetylation of histone H3 in MPC cells at the same doses of romidepsin or trichostatin A that had been demonstrated to decrease (Fig. 3A) . Neurosecretory granules were present, but no differences were noted between control and treated cells (Fig. 3B) .
MRI imaging
MRI detected multiple liver lesions in our in vivo model. Liver lesions R4 mm in diameter were present 5 weeks after tail vein injection of MPC cells and were suitable for PET imaging. Moreover, we were able to determine the growth of individual lesions and correlate radionuclide uptake with the size of the lesions. (Fig. 4) . (Fig. 5D ). A number of HDAC inhibitors induce growth arrest, differentiation, and/or apoptosis in various tumor cell lines and in vivo (Marks et al. 2001) . Voronistat (Zolinz a , Patheon, Inc., Mississauga, ON, Canada) and romidepsin (Istodax, Celgene, Summit, NJ, USA) are now approved for the treatment of cutaneous T-cell lymphoma as single agents (Mann et al. 2007 , Piekarz et al. 2009 ). HDAC inhibitors are also being studied in combination with cytotoxic or cell cycle modulating agents, monoclonal antibodies, or radiotherapy (Piekarz et al. 2006 , Chen et al. 2009 ).
Current treatment options for malignant pheochromocytoma and paraganglioma are limited, and responses are often transient (Averbuch et al. 1988 , Kopf et al. 1997 , Loh et al. 1997 , Sisson et al. 1999 , Pacak et al. 2001b , Munver et al. 2003 . The success of [ 131 I]MIBG, the most frequently applied therapy, depends on the drug dose and schedule used (Rose et al. 2003 , Safford et al. 2003 . Response rates are increased with higher doses of [ 131 I]MIBG (Fitzgerald et al. 2006) , but higher doses are associated with greater toxicity and increased long-term risk of second malignancy (Rose et al. 2003 , Safford et al. 2003 .
A For the biodistribution studies, trichostatin A was administered twice, 24 and 2 h before [
18 F]fluorodopamine injection because of the rapid and extensive metabolism of trichostatin A. It was demonstrated that, following i.p. administration to mice (Sanderson et al. 2004) , trichostatin A was rapidly absorbed from the peritoneum and was detectable in plasma within 6-9 min. To translate these results into clinical studies, the half-life of the HDAC inhibitors should be taken into consideration. From the present results, we conclude that romidepsin, given its recent FDA approval and longer half-life, would be more suitable for human study than trichostatin A.
Our original approach for HDAC inhibitor pretreatment was carried out using the protocol described by Goldsmith et al. (2007) , where female athymic nude mice were treated with romidepsin at a dose of 3.6 mg/kg. Twenty-four hours following a single romidepsin injection, increased coxsackie adenovirus L Martiniova, S M Perera et al.: Histone deacetylase inhibitors and PHEO www.endocrinology-journals.org receptor levels were observed, histone H3 acetylation, in athymic mice bearing human melanoma xenografts. In our experimental design, mice were given anesthesia and injection of [ 123 I]MIBG and [ 18 F]fluorodopamine, and imaged 24 h following a dose of romidepsin or trichostatin A. However, if the dose of 3.6 mg/kg as bolus was injected into mice with liver pheochromocytoma metastases, toxic effects such as tachycardia, irregular breathing, and tremor were observed and up to 30% of mice did not survive the imaging study. Thus, a single lower dose of romidepsin (2.5 mg/kg) was administered to evaluate its effect on isotope accumulation in the tumors. Mentioned toxicity from the romidepsin pretreatment per se could have also been as a result of increased levels of catecholamine, epinephrine, and norepinephrine. Along with [ 123 I]MIBG and [
18 F]fluorodopamine injections, a stress response also was created when mice were handled. All these effects have been observed previously in imaging studies. Owing to extensive liver metastases and the low percentage of healthy liver parenchyma, anesthesia itself can be toxic (Martiniova et al. 2009a) . [
131 I]MIBG treatment does not require any anesthesia, and it would not be used in patients undergoing any surgical procedure that requires anesthesia.
In our in vitro study, there is also visible dose dependency. The FDA approved clinical doses are 14 mg/m 2 body surface administered on days 1, 8, and 15 of a 28-day cycle, and are designed for longitudinal dosing of patients. If one does the calculations for an average weight mouse (w25 g), a single standard human dose of romidepsin is 14 mg/m 2 Z14 mg !1.73 m 2 body surface area (the average human male body surface area)Z24.2 mg total single dose divided by the ideal male body weight (80 kg); 24.2 mg/80 kg, the typical human dose of romidepsin is Z0.3 mg/kg per dose. If one considers that three doses are given per treatment cycle over 15 days, then the patients receive a total dose of 0.9 mg/kg. We used a single dose of 2.5 mg/kg or approximately threefold greater. In mouse studies, other investigators have used doses of romidepsin that ranged from 0.1 to 50 mg/kg. The therapeutic doses used in other animal studies were 1 and 2.5 mg/kg respectively (Hirokawa et al. 2005a ,b, Chen et al. 2008 .
Mice and humans often handle the same drugs very differently, so the drug dosing may be different. Therefore, for the clinical trial we are planning, the doses will be much lower with dose escalation and will be administered as infusion with more cycles than a single dose.
Our results raise the possibility of using romidepsin to increase the sensitivity of pheochromocytoma and paraganglioma lesions to [ 131 I]MIBG treatment. Future studies will focus on determining the optimal timing and dose of romidepsin. Ideally, synergy between romidepsin and [ 131 I]MIBG would allow both drugs to be used at lower concentrations than usually used as a single agent. Since romidepsin will not be used as a monotherapy, but as a sensitizer, only a few doses well below, which associates with toxic effects, will be administered before [
131 I]MIBG treatment (Piekarz et al. 2006 , Molife et al. 2007 .
In summary, treatment with HDAC inhibitors increases radioisotope uptake in MPC cells in vitro and in vivo through both increased expression of the norepinephrine transporter and enhanced retention in cytoplasmic neurosecretory granules. These results suggest that HDAC inhibitors might be used to increase the response of patients with malignant pheochromocytoma and paraganglioma to [
131 I]MIBG treatment. The same approach also could be used to increase the sensitivity of [ 131 I]MIBG scintigraphy for detecting metastatic lesions in these patients. Pretreatment with romidepsin also could be beneficial to those patients whose tumors do not take up [
123 I]MIBG thus increasing the sensitivity of this diagnostic approach. HDAC inhibition may also help to overcome the loss of norepinephrine transporter expression that might occur with chemotherapy treatment, similar to what happens with 131 I treatment of thyroid cancer (Beierwaltes 1987 , Simon et al. 2002 , Gruning et al. 2003 . Clinical studies are in progress to investigate these options.
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